The Effects of LY2409021 on the Liver

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study that involves multiple doses of study drug (60 mg of LY2409021, 15 mg of LY2409021 or placebo) taken as capsules by mouth on a daily basis for 28 days. This study will image the liver using magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) in healthy participants and in participants with type 2 diabetes mellitus, when they take LY2409021 to see if liver changes happen at the same time as changes in blood tests. This study is approximately 11 weeks long, not including screening. A screening appointment is required within 28 days prior to the start of the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

NCT05882032

Healthy Hepatic Insufficiency

COMPLETED PHASE1

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases

NCT05599945

Healthy Volunteers Hepatic Steatosis

COMPLETED PHASE1

Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease

NCT06739486

Non Alcholic Fatty Liver Disease Hepatic Steatosis Hepatic Fibrosis +1 more

NOT_YET_RECRUITING

Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients

NCT03205150

Obese Patients With Non-alcoholic Steatohepatitis (NASH)

COMPLETED PHASE2

A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.

NCT05857644

Liver Diseases Hepatic Impairment

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Part A and B - Up to 4 capsules of placebo administered orally once a day for 28 days.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally

15 mg LY2409021

Part B - 1 capsule of 15 mg LY2409021 orally once a day for 28 days. (Arm added in September, 2012, per protocol amendment.)

Group Type EXPERIMENTAL

LY2409021

Intervention Type DRUG

Administered orally

60 mg LY2409021

Part A - 4 capsules of 15 mg LY2409021 administered orally once a day for 28 days.

Group Type EXPERIMENTAL

LY2409021

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Administered orally

Intervention Type DRUG

LY2409021

Administered orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For all participants:

* Must be a male, or a female who cannot become pregnant, and who is either a healthy participant, or who has type 2 diabetes
* Must have a body mass index (BMI) of 18.5 to 29.9 kilograms per square meter (kg/m\^2) if a healthy participant, or a BMI of 18.5 to 35.0 kg/m\^2 if diabetic

For participants with type 2 diabetes mellitus (T2DM):

\- On diet and exercise treatment, or taking metformin

Exclusion Criteria

For all participants:

* Have signs or symptoms of liver disease
* Are infected with hepatitis B or hepatitis C
* Have donated more than 450 mL of blood in the last 3 months or if have donated any blood in the last month
* Smoke more than 10 cigarettes per day or are not willing to abstain from smoking while at the clinic
* Have had surgery with metallic clips, staples or stents, or have had a cardiac pacemaker (or other surgical implants) inserted in any part of the body, or have fear of enclosed spaces or have symptoms that prevent them from being sent for an magnetic resonance imaging (MRI) scan

For participants with T2DM:

\- Are using insulin

Minimum Eligible Age

21 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes